ÂÜÀòÂÒÂ×

Daniel Delubac is a seasoned leader, manager & engineer specialized in biotechnology. His experiences span clinical diagnostics research, product development & lab operations, as well as synthetic biology.

He started his career at Counsyl, where he built the first fully automated, blood-to-data, robotic system for clinical-grade Next Generation Sequencing. He then joined Guardant Health where he supervised both process engineer at the company level and automation for sample processing, ensuring the company’s capabilities to scale efficiently, while preparing his functions for a FDA supervision. At Freenome, he led execution on the wetlab R&D, process engineering, automation, laboratory operations, supply chain, building next generation products for the unbiased discovery of cancer biomarkers using robotics and AI. Eventually, he facilitated product development at the company level. Daniel now serves as COO @ Xilis where he is developing the future of cancer care utilizing micro-organoids.

He also serves as an advisor to a variety of biotech start-ups & scale-ups, providing guidance on organizational & operational matters.

Outside of work, Daniel is a dedicated father & husband, spending most of his non-startup hours with family.

Daniel holds a B.S. and M.S. in Applied Physics from France, and a Ph.D. in biomedical engineering from Carnegie Mellon University.